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Abstract 
Protein Glycan Coupling Technology (PGCT) uses purposely modified bacterial cells to produce recombinant glyco-
conjugate vaccines. This vaccine platform holds great potential in this context, namely due to its modular nature, the 
simplified production process in comparison to traditional chemical conjugation methods, and its amenability to 
scaled-up operations. As a result, a considerable reduction in production time and cost is expected, making PGCT-
made vaccines a suitable vaccine technology for low-middle income countries, where vaccine coverage remains 
predominantly low and inconsistent. This work aims to develop an integrated whole-process automated platform for 
the screening of PGCT-made glycoconjugate vaccine candidates. The successful translation of a bench scale process 
for glycoconjugate production to a microscale automated setting was achieved. This was integrated with a numeri-
cal computational software that allowed hands-free operation and a platform adaptable to biological variation over 
the course of a production process. Platform robustness was proven with both technical and biological replicates and 
subsequently the platform was used to screen for the most favourable conditions for production of a pneumococcal 
serotype 4 vaccine candidate. This work establishes an effective automated platform that enabled the identification 
of the most suitable E. coli strain and genetic constructs to be used in ongoing early phase research and be further 
brought into preclinical trials.
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Introduction
Vaccines are successful prophylactics that have greatly 
reduced the burden of disease worldwide. Conservative 
estimates from the World Health Organisation (WHO) 
suggest that vaccination saves at least 2–3 million lives 
every year [1], thus providing an invaluable cost-effective 
strategy in infectious disease prevention. Numerous vac-
cine technology platforms exist, these mainly include 
whole cell live attenuated vaccines (LAVs); inactivated 
vaccines; and subunit vaccines, where a few elements of 
the targeted pathogen trigger an immune response. Gly-
coconjugate vaccines are subunit vaccines consisting of 
a cell surface glycan, such as capsular polysaccharides 
(CPS), or O-antigens, covalently linked to an immu-
nogenic carrier protein. These are amongst the safest 
and most efficacious vaccines in use today. In contrast 
to polysaccharide subunit vaccines, which are partially 
immunogenic in adults only, glycoconjugates effectively 
confer protection in both children and the elderly, two 
categories most ‘at-risk’ from infectious disease [2–7]. 
Pivotal research from Avery and Goebel in the 1930s [3, 
4], together with the success of glycoconjugates intro-
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of conjugation between the glycan and protein moiety in 
determining the immunogenicity of the vaccine.
The current production process of conjugate vaccines 
is a complex, multi-step process involving separate culti-
vations of a pathogenic strain to harvest glycan antigens, 
and of a second strain expressing the carrier protein. 
Two distinct purification chains are then needed before 
pre-treatment of the two components for chemical con-
jugation. This is followed by a final purification chain to 
obtain the purified glycoconjugate. The need for at least 
three full purification sequences makes production of 
glycoconjugate vaccines costly, time consuming, prone to 
product loss and often yields contaminated preparations 
and batch to batch variation, given the random nature of 
chemical coupling. Due to these inefficiencies, vaccine 
coverage in predominantly low-middle income countries 
(LMICs) remains inconsistent [1]. For example, in 2017 
pneumonia was responsible for the deaths of 2.56 million 
people, a third of whom were below 5 years, despite there 
being effective vaccines on the market targeted against 
Streptococcus pneumoniae, the leading cause of pneumo-
nia [8–10]. Pneumococcal conjugate vaccines are unaf-
fordable for many LMICs that lose support of the Global 
Alliance for Vaccines and Immunisation (GAVI) for 
reduced pricing ($3.05–$169 /dose for GAVI-supported 
countries to high income countries) [11]. Moreover, the 
geographic distribution of pneumococcal serotypes var-
ies and serotypes not covered by the current vaccines are 
increasingly causing disease, a phenomenon known as 
serotype replacement [12, 13]. This further increases the 
demand for affordable vaccines that can be easily tailored 
to the targeted area/population.
Bacterial genetic engineering has allowed the recent 
development of Protein Glycan Coupling Technology 
(PGCT), which relies on the in vivo coupling of recom-
binant glycan antigens to an immunogenic carrier pro-
tein when co-expressed with an oligosaccharyltransferase 
(OST) enzyme in an E. coli cell (reviewed in [14, 15]). 
With an inexhaustible and homogenous preparation of 
the glycoconjugates formed within the purposely engi-
neered strains of E. coli, the overall production process is 
simplified to a single purification sequence from cell har-
vest. This is expected to considerably reduce production 
costs, thus making PGCT a suitable vaccine technology 
for LMICs and for the veterinary market. PGCT-made 
glycoconjugates have shown success both in preclinical 
and clinical trials, for an exhaustive overview see Table 3 
in [14], however no streamlined production platform 
is publicly available. One of the biggest hurdles to vac-
cine commercialisation is the high demand on time and 
resources. During vaccine development, the research 
and development phase alone is estimated to last up to 5 
years and include hundreds of candidates. The duration 
of this phase can vary greatly and incorporates the estab-
lishment of a vaccine antigen/identity and the production 
process [17]. During an epidemic or pandemic scenario 
rapid response in finding the right vaccine candidate 
is vital and timescales must be vastly reduced, as seen 
with the recent SARS-CoV-2 outbreak. PGCT holds 
great potential in this context given its modular nature, 
the simplified production process and its amenability to 
scaled-up operations. In addition, automated screening 
methodologies have proven invaluable for improved pro-
ductivity and reproducibility [18–20], however a balance 
is often needed between flexibility and complexity to 
attain a precision platform that can suitably adapt to the 
inherent biological variation associated with cell culture.
The rapid and reliable screening of novel vaccine can-
didates is central to minimising costs and to speed up 
the research and development phase in vaccine manu-
facture. The process developed is equally critical as the 
product, and both must be optimised for successful 
manufacturing. Recognising this at an international level, 
the IPROVE (Innovation Partnership for a Roadmap on 
Vaccines in Europe) FP7 project drew attention to the 
potential benefits of building a fully multi-disciplinary 
vaccine research community. The FP7 project, covering 
vaccine discovery, development, production and access, 
set out 80 key recommendations to achieve its mandate 
of affordable, faster, more flexible and less wasteful vac-
cine production in Europe. Among the recommenda-
tions, there was a recurring theme of close collaboration 
needed amongst scientists, engineers and regulators for 
improvement in vaccine manufacturing, innovation and 
quality control [16]. Importantly, this work represents 
a close collaboration between molecular biologists and 
biochemical engineers for vaccine design and process 
development. We present an integrated whole-process 
automated platform for the screening of PGCT-made 
glycoconjugate vaccine candidates, aimed for eventual 
transfer to a low-income setting. The platform will be 
accessible to non-automation experts to deploy an auto-
mated workflow and will provide a powerful tool in the 
early research and development phase of this work.
Materials and methods
Bacterial strains, growth conditions and plasmids
Electrocompetent Escherichia coli K-12 strains 
(W3110, CLM37, CLM24, SDB1 and Falcon) were 
transformed with plasmids encoding the three PGCT 
components (glycan, carrier protein and PglB OST) in 
1 mm gap cuvettes at 2 kV, 200 Ω and 25 µF. Strains 
were grown in Lysogeny Broth (LB) or on LB agar at 
37 °C with the required antibiotics at the following 
concentrations: 100 µg/mL ampicillin, 20 µg/mL tetra-
cycline and 50 µg/mL kanamycin. E. coli DH5α were 
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used as a host for cloning experiments. Colony form-
ing units (CFUs) of PglB-induced and uninduced Fal-
con cultures were determined in biological triplicates. 
Briefly, cultures were matched at an optical density 
measured at 600 nm  (OD600) and tenfold serial dilu-
tions were performed for each sample  (100–10–7). 2 µL 
of each dilution were spotted in technical triplicates 
on dry LB agar plates containing the appropriate anti-
biotics. Colonies were counted after O/N incubation at 
37 °C and CFU/mL were calculated.
Pseudomonas aeruginosa exotoxin A was modi-
fied according to [21] to obtain a detoxified version 
containing two internal PglB glycosylation sequons. 
The genetic sequence encoding for the modified pro-
tein was codon optimised for E. coli and ordered via 
gene synthesis from GenScript. The sequence was 
N-terminally fused to either DsbA or PelB signal pep-
tide for secretion to periplasm, and a 6xHis tag was 
added C-terminally. DsbA-ExoA(10) has eight extra 
optimal PglB glycosylation sequons (DQNAT), four 
added N-terminally downstream of the signal pep-
tide and four added C-terminally upstream of the 
His-tag spaced by “GG” duplets. The sequence was 
also ordered via gene synthesis from GenScript. Con-
structs were subcloned into pEC415 or pEXT20 vec-
tor via restriction enzyme digest using NheI-EcoRI 
and EcoRI-BamHI, respectively (High Fidelity ver-
sions, New England Biolabs). Details on all strains and 
plasmids used in this study can be found in Additional 
file 1: Tables S1 and S2, respectively.
All strains used during the strain screening in ‘Appli-
cation of the automated platform for screening studies’ 
section are referred to as in Table 1.
Inoculum preparation
A 1 mL 40% glycerol working cell bank was used to 
inoculate a 50 mL falcon tube containing 10 mL of LB, 
supplemented with the antibiotics listed in “Bacterial 
strains, growth conditions and plasmids” section. The 
preculture was incubated at 37 °C overnight (O/N, 
≈ 16 h) with agitational speed (N = 180 rpm) on an 
orbital shaker platform (orbital diameter, do = 25 mm). 
Unless otherwise specified, all reagents used in this 
work were obtained from Sigma-Aldrich, Switzerland.
Production of glycoconjugates at the bench scale
For production of glycoconjugate at the bench scale, cell 
culture was performed in cylindrical falcon tubes with 
a conical bottom geometry. The preculture was used to 
inoculate 20 mL of LB media, supplemented with the 
antibiotics listed in “Bacterial strains, growth condi-
tions and plasmids” section, to a liquid height, HL = 45.5 
mm and an  OD600 of 0.045. Cultures were grown at 37 
°C, N = 180 rpm to an  OD600 of 0.6–0.8 (late exponential 
phase). Expression of PglB and ExoA were induced with 
the addition of 1 mM IPTG and 0.4% (w/v) l-arabinose, 
respectively, before the culture was grown at 28 °C for 
a further 20 h on an orbital shaker platform. Cells were 
then harvested by centrifugation for 15 min at 3000×g 
at either 4 °C or 22 °C, depending on which subsequent 
periplasmic buffer was used (lysozyme-based method or 
heat-based method), as described in “Periplasmic extrac-
tion” section. The supernatant was discarded, and the cell 
pellets were resuspended in periplasmic buffer, according 
to the protocols detailed in “Periplasmic extraction” sec-
tion. Following periplasmic extraction, a final centrifuga-
tion step was performed at 5000×g and 4 °C for 15 min 
and the supernatant used for western blot analysis. Fig-
ure 1a illustrates the bench scale production platform.
Production of glycoconjugates at the microscale
For production of glycoconjugate at the microscale, cell 
culture was performed in 24-deep square well plates (24-
DSW). Each well has a square geometry and a truncated 
pyramid bottom. The preculture was used to inoculate 
2 mL/well of LB media, supplemented with the antibi-
otics listed in “Bacterial strains, growth conditions and 
plasmids” section to a liquid height, HL = 6.9 mm and 
an  OD600 of 0.045. To limit liquid evaporation and cross 
contamination between the wells, whilst ensuring suf-
ficient oxygen transfer, Duetz-system sandwich covers 
were used (Kuhner Shaker, Switzerland). The culture was 
grown at 37 °C on a Thermomixer Comfort agitated at 
N = 300 rpm (do = 3 mm) to an  OD600 of 0.6–0.8 (Eppen-
dorf, Germany). Expression of PglB and ExoA were 
induced with the addition of 1 mM IPTG and 0.4% (w/v) 
l-arabinose, respectively, before the culture was grown 
for 20 h at 28 °C, N = 300 rpm. Each plate was then 
centrifuged for 15 min at 4300 × g and at 4 °C or 22 °C, 
depending on which subsequent periplasmic buffer was 
Table 1 Identifiers used for the various strains of E. coli studied
Strain W3110 CLM37 CLM24 SDB1 Falcon









Identifier Strain 1 Strain 2 Strain 3 Strain 4 Strain 5 Strain 6
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used, as described in “Periplasmic extraction” section. 
The supernatant was removed, and the remaining cell 
pellets were resuspended in periplasmic buffer, accord-
ing to the protocols detailed in “Periplasmic extraction” 
section. For Periplasmic Buffer 1 (PB1) it was necessary 
to transfer the resuspended cell pellets from each well 
to separate tubes for agitation on a roller mixer at 4 °C. 
Periplasmic Buffer 2 was used to resuspend the cell pel-
lets in situ and agitation/heating was achieved using the 
thermomixer. Following periplasmic extraction, a final 
centrifugation step was performed at 5000×g and 4 °C 
for 15 min and the supernatant used for western blot 
analysis. Figure  1b illustrates the microscale production 
platform.
Periplasmic extraction
Following cell harvest, the resultant pellet from each 
culture condition was resuspended in periplasmic 
Fig. 1 a-b Process steps for glycoconjugate production at the bench scale (a) and the microscale (b). c Top-view schematic representation of the 
automated worktable depicting the carriers and labware, including disposable tips (DiTis), 96-standard round well plate (SRW) and 24-deep square 
well plate (DSW)
Page 5 of 15Samaras et al. Microb Cell Fact          (2021) 20:104  
extraction buffer to a matched  OD600 value of 20 per 
tube or well. This ensured that cell biomass prior to 
periplasmic extraction was normalised across all sam-
ples. Periplasmic extracts were prepared using either 
lysozyme treatment, as described in Feldman et  al. 
(Periplasmic buffer 1, PB1), or a heat-based method 
from Bowering et  al. (Periplasmic buffer 2, PB2) [22, 
23]. The lysis buffer (PB1) was composed of an initial 
preparation of 30 mM Tris–HCl pH 8.5, 1 mM EDTA 
and 20% (w/v) sucrose. This was then sterile filtered 
(0.22 µm, UltraCruz® Syringe Filter) and fresh addi-
tions of lysozyme (1 mg/mL) and cOmplete™ mini 
EDTA-free protease inhibitor cocktail (1 tablet/10 mL, 
Roche, Switzerland) were made before incubation at 
4 °C for 0.5 h with agitation. Periplasmic extraction 
buffer 2 (PB2) was composed of sterile filtered 100 mM 
Tris–HCl pH 7.4 and 10 mM EDTA and samples were 
incubated for 1 h with agitation at 30 °C. The com-
position of each periplasmic buffer is summarised in 
Table 2. To improve upon periplasmic extraction yields, 
a range of alternative combinations of temperature (T) 
and incubation time (t) were investigated, these are 
given in Table 3.
Fluorescent western blotting
To verify glycoconjugate production, periplasmic extracts 
were analysed by SDS-PAGE and western blotting. Equal 
volumes of samples, previously normalised by optical 
density, were used. This enabled semi-quantitative com-
parison between samples on one blot. Samples were ini-
tially prepared with LDS sample buffer and separated on 
4–12% bis–tris gels in MOPS buffer (Invitrogen, USA). 
The gels were then electroblotted onto a nitrocellulose 
membrane using a Trans-Blot Turbo Transfer System 
(Bio-Rad, USA). Rabbit anti-serotype 4 capsule antibody 
(Statens Serum Institut, Denmark) was used at a dilu-
tion of 1:1000 and mouse anti-His monoclonal antibody 
(Thermo Fisher Scientific, USA) was used at a dilution of 
1:10,000 to detect recombinant serotype 4 capsule and 
His-tagged ExoA, respectively. Secondary goat anti-rab-
bit IgG IRDye 800 and goat anti-mouse IgG IRDye 680 
conjugates (LI-COR Biosciences, USA) were used at a 
dilution of 1:10,000. Fluorescent signal in two channels, 
700 and 800 nm, was detected with an Odyssey CLx LI-
COR detection system, using a solid-state diode laser at 
wavelengths 685 and 785 nm, respectively (LI-COR Bio-
sciences, USA). Subsequent semi-quantitative densitom-
etry analysis of the glycoconjugates was performed using 
the Image Studio (LI-COR Biosciences, USA) analysis 
tool, as demonstrated in the supplementary material 
(Additional file 2: Figure S1).
Sandwich ELISA
Semi-quantitative analysis of ExoA-CPS4 glycoproteins 
in periplasmic extracts matched by optical density were 
performed by sandwich ELISAs with a protocol modi-
fied from [24]. Transparent polystyrol 96-well plates with 
high protein binding capacity (F96 MaxiSorp, Nunc) 
were coated with goat polyclonal P. aeruginosa Exotoxin 
A antibody (Fitzgerald, USA) diluted 1:1000 in PBS (100 
µL/well) and incubated overnight at 4 °C. Wells were 
then washed four times with 200 μL PBS-T (0.1% Tween-
20) for 2 min static and 2 min 500 rpm, and blocked for at 
least 2 h at room temperature with 200 μL 10% (w/v) milk 
in PBS-T per well. After blocking, wells were washed 
twice as described above and 60 µL/well of periplasmic 
extract was added to the plate and incubated overnight at 
Table 2 Composition of Periplasmic Buffers (1) and (2)
Components Periplasmic Buffer 1 Periplasmic Buffer 2
Tris.HCl 30 mM (pH 8.5) 100 mM (pH 7.4)
Sucrose 20% (w/v) -
EDTA 1 mM 10 mM
Lysozyme 1 mg/mL (fresh) -
Protease inhibitor cocktail 1 tablet/10 mL (fresh) -
Table 3 Periplasmic extraction methods tested
a The prefix for each condition represents Periplasmic Buffer 1 or 2. The 
subsequent letter (A–M) distinguishes the different conditions, changing 
either duration (t), temperature (T) or protease inhibitor tablet addition during 
periplasmic extraction. ‘O/N’ shows overnight incubation of ~ 16 h
Conditiona t [h] T [°C] Protease 
inhibitor 
[Y/N]
Control 0.5 4 Y
1A 0.5 4 N
1B 1 4 Y
1C 1 4 N
1D 0.5 22 Y
2A O/N 60 Y
2B O/N 22 Y
2C O/N 22 N
2D O/N 30 Y
2E O/N 30 N
2F 1 60 Y
2G 1 60 N
2H 1 45 Y
2I 1 45 N
2 J 1 30 Y
2 K 1 30 N
2L 1 22 Y
2 M 1 22 N
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4 °C. Prior to addition to the plate, periplasmic extracts 
were diluted 1:100 in 50 mM  Na2CO3 pH 9.6 and treated 
with 2% Triton X-114 to remove lipid-bound CPS4 as 
described in [25]. Unbound ExoA was removed with 
four washes performed as described above. To quantify 
the CPS4 glycan and ExoA protein content of ExoA-
CPS4 glycoproteins rabbit anti-CPS4 antiserum (Statens 
Serum Institut, Denmark) and mouse monoclonal anti-
His (Thermo Fisher Scientific, USA) were added to sepa-
rate wells of duplicated samples at a 1:1000 dilution in 1% 
(w/v) milk in PBS-T. The plate was then incubated for 2 
h at room temperature, N = 500 rpm. Unbound antibod-
ies were removed by four washes as previously described. 
Detection antibodies goat-anti-rabbit IgG-HRP (Abcam, 
UK) and rabbit-anti-mouse IgG-HRP (Sigma-Aldrich, 
Switzerland) were added at 1:10,000 dilution in 1% (w/v) 
milk in PBS-T, incubated for 1 h at room temperature, 
and unbound antibodies were removed by four washes. 
ELISA plates were developed with 100 µL/well TMB 
substrate solution (Invitrogen, USA). The oxidative reac-
tion was stopped by adding 100 µL/well  H2SO4 (2 N) and 
absorbances at 450 nm were detected using a SpectraMax 
iD5 plate reader (Molecular Devices, USA).  OD450 back-
ground values (buffer only in wells treated as the rest, or 
proteinase K-treated extracts) were subtracted from test 
values, triplicates or hexaplets were averaged and error 
bars represent standard deviations. All ELISAs were per-
formed in duplicate.
Proteinase K digestion
50 µg/mL of proteinase K (10 mg/mL) was added to peri-
plasmic extracts to digest their proteome. Samples were 
incubated in a water bath at 55 °C for 1 h, after which 
they were used for downstream analysis.
Automated microscale platform
A Tecan Freedom Evo 150 base station programmed 
and controlled by Freedom EVOware® version 2.6 was 
equipped with an eight-channel liquid handling (LiHa) 
arm and an eccentric robot manipulator (RoMa) arm 
(Tecan, Switzerland). The LiHa was fitted with disposable 
tips (DiTi) and the RoMa was used for plate manipula-
tion around the platform. Figure 1b depicts the sequence 
of operations to be performed on the platform, excluding 
the western blot analysis. The platform was integrated 
with an Infinite M200 plate reader, operated by Magel-
lan™ software version 7.2 (Tecan Group Ltd.), a Rotanta 
46 RSC microwell centrifuge (Hettich, Germany) and 
a Thermomixer Comfort (Eppendorf, Germany), all of 
which were enclosed within a Class II biosafety cabinet.
A top-view representation of the worktable is given in 
Fig. 1c, showing the positions of all the carriers and lab-
ware required for a complete production run. It is worth 
noting that in total two 24-DSW plates were used, one 
for a balance plate during centrifugation and one used 
for culture, which was moved by the RoMa between the 
thermomixer for heated agitation and the carrier for 
larger volume additions (> 200 µL), corresponding to grid 
positions 20 and 14, site 3, respectively (see Fig. 1c).
An EVOware script was developed for ‘walk-away’ 
unsupervised operation for all process steps, excluding 
western blotting (Fig.  1b). The script includes conven-
tional commands and worklists, and is able to self-exe-
cute applications for calculation, decision-making, 
worklist creation and report generation of biomass 
growth over the course of cell culture. The executable 
application was created using a purposely written Matlab 
code and compiled using the Matlab Compiler™ (Math-
works, USA, release 2019b).
Results and discussion
Identification of a scalable periplasmic extraction 
methodology for PGCT‑made glycoconjugate vaccines
The aim of this work was the development of an auto-
mated microscale screening platform for PGCT-made 
glycoconjugate vaccines, currently obtained from a bench 
scale production process. The prototype glycoconjugate 
vaccine analysed in this study is a pneumococcal vac-
cine against serotype 4 composed of carrier protein ExoA 
covalently attached to the capsular glycan of serotype 4 
pneumococcus. More specifically, a genetically detoxified 
variant of P. aeruginosa Exotoxin A N-terminally fused to 
a signal peptide for periplasmic expression, C-terminally 
fused to a hexahistidine tag and genetically engineered 
with N-glycosylation sites was used [26, 27]. The presence 
of glycosylation sequons turns the modified ExoA into a 
substrate for N-linked glycosylation with S. pneumoniae 
capsular polysaccharide of serotype 4 (CPS4) when co-
expressed with the oligosaccharyltransferase PglB from 
Campylobacter jejuni, which functions in the periplasm 
of gram-negative bacteria. Previous work has demon-
strated CPS4 bioconjugates to confer protection against 
a homologous pneumococcal strain in murine models, 
and the carrier protein ExoA to be a suitable candidate 
for production at scale [26, 28, 29].
To develop the screening platform, all process steps 
needed to first be translated to the microscale and be 
amenable to automation. The main bottleneck was the 
lysozyme-based periplasmic extraction step, which 
although could be scaled down, could not be performed 
without manual input, namely due to the fresh additions 
of lysozyme and protease inhibitor enzymes. Addition-
ally, the lysozyme-based extraction protocol required 
a cold incubation step at 4 °C, which was problematic 
on the automated platform. Both the fresh additions of 
enzymes and the requirement for cold incubation are 
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better avoided when considering eventual scale-up of the 
process due mostly to their high cost. A number of alter-
native methodologies were found in the literature and a 
simple heat-based methodology, introduced in the work 
of Bowering et al. [23], was considered the most appro-
priate. The protocol, outlined in “Periplasmic extraction” 
section, was amenable to both automation and large scale 
processes and had been proven to work for extraction of 
antigen-binding fragments (Fab’) at a range of tempera-
tures [23, 30]. An initial investigation between the ‘con-
trol’ condition, consisting of a sample that underwent 
lysozyme-based extraction for 0.5 h incubated at 4 °C 
with a protease inhibitor tablet added (see Table 3), and a 
sample that underwent heat-based extraction, incubated 
for 1 h at 30 °C (condition 2 K, Table 3), is presented in 
Fig. 2a and b. Each condition was performed in triplicate 
before the periplasmic extracts were separated by SDS-
PAGE and analysed by western blotting, shown in Fig. 2a. 
Bearing in mind the later application of the protocol to 
microscale cultures, a heavily glycosylatable version of 
ExoA with 10 glycosylation sequons was used to max-
imise glycosylation detection (similar to Marshall et  al. 
[27]). ExoA(10)-CPS4 glycoproteins run at ≈ 100 kDa 
(lanes 2–4 and 6–8 of Fig.  2a). Lanes 5 and 9 show the 
sample following digestion with proteinase K, where the 
absence of the glycoconjugate confirmed the anchor-
age of the CPS4 glycan to the ExoA carrier protein. The 
CPS4 visible at the bottom of the blot is still detected in 
proteinase K-treated samples indicating it is not protein-
bound. An initial comparison between the two periplas-
mic extraction techniques, based upon semi-quantitative 
densitometry analysis/pixel intensities from the western 
blotting, showed a statistically significant 40–60% reduc-
tion in product yield using the heat-based extraction 
protocol (Fig. 2a, right). This reduction in product yield 
was confirmed using a second semi-quantitative tech-
nique, a sandwich ELISA measuring ExoA-CPS4 glyco-
protein from periplasmic extracts. The ELISA showed 
a 30% decrease in CPS4 glycan coupled to ExoA and ≈ 
56% decrease in the extracted ExoA protein with the 
Fig. 2 Comparison of different periplasmic extraction methods. a Western blotting and densitometry analysis showing the presence and recovery 
of ExoA-CPS4 glycoproteins obtained with both the lysozyme and heat-based methods of periplasmic extraction. Lanes 5 and 9: Proteinase K 
digests. Relative quantification based on pixel intensity; b Semi-quantitative sandwich ELISA analysis of ExoA-CPS4 glycoproteins in periplasmic 
extracts. ExoA-coupled CPS4 glycan and ExoA protein (His) were quantified independently. Statistical significance (*) using an unequal variance 
two-tailed t-test is considered in all experiments when p ≤ 0.05; c Western blotting showing the presence of ExoA-CPS4 glycoproteins in 
periplasmic extracts obtained with some of the conditions listed in Table 3 and densitometry results of protein (red) and glycan (green) quantities 
based on pixel intensity normalised to the control condition
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heat-based extraction protocol in comparison to the 
lysozyme-based extraction method (Fig. 2b). The discrep-
ancies observed between the densitometry and ELISA 
estimates are as a result of the advantages and limita-
tions associated with each method. ELISA assays are 
highly sensitive and specific, with a readout based on a 
time sensitive enzyme/substrate reaction. Densitometry 
analysis of fluorescent blots are time-independent, how-
ever are less sensitive to weaker signals when masked 
by stronger intensities. Both methods were adopted to 
independently validate our observations. Importantly, 
despite the difference in estimates, conclusions drawn 
from both methods are in agreement. Whilst product 
recovery was reduced, this revealed a potential method 
for simplified periplasmic extraction, amenable to both 
automation and scale-up. The glycan to protein ratio in 
the recovered product was also increased. To investigate 
whether improved recovery could be achieved, a range of 
conditions were tested, summarised in Table  3. Incuba-
tion temperature was varied between 22 °C (room tem-
perature)–60 °C with either overnight (≈ 16 h) or 1 h 
incubation periods. Figure  2c shows a western blotting 
comparing multiple periplasmic extraction conditions. 
Through densitometry analysis it was possible to esti-
mate the variation in periplasmic extraction performance 
for all the conditions tested (see Table 3). Figure 2e gives 
the relative yield of the conditions investigated, where 
the prefix for all conditions represents either Periplasmic 
Buffer 1 (lysozyme-based method) or Periplasmic Buffer 
2 (heat-based method). Considering the best performing 
condition for the lysozyme-based extraction protocols 
(condition 1A), an approximate 40% increase in product 
recovery was achieved in comparison to the control. In 
both cases the sample was incubated at 4 °C for 0.5 h with 
and without the addition of the protease inhibitor cock-
tail (control and sample 1A, respectively). Interestingly, 
the addition of the protease inhibitor cocktail reduced 
variability when used with the heat-based periplas-
mic extraction methodology, whilst product expression 
remained mostly unchanged. The fresh addition could 
not be achieved on an automated platform however, and 
it is generally preferable at larger scales to exclude such 
costly additions, thus conditions without protease inhibi-
tors were selected. Of the heat-based extraction condi-
tions investigated (Fig. 2c), three conditions were shown 
to provide relatively good product recovery in compari-
son to the control. For overnight incubation (≈ 16 h) and 
heating to either 22 °C (2C) or 30 °C (2E) product recov-
ery reached approximately 82% or 87% of the control 
condition, respectively. Shorter incubation times for 1 h 
at 45 °C (2I), whilst not as effective, still achieved approx-
imately 60% product recovery in comparison to the con-
trol. Overall, although a reduction in product recovery 
was observed, a viable alternative methodology was 
found which was simpler to perform, amenable to auto-
mation and feasible to use with process scale-up.
Establishment of an automated screening platform
Manual process translation and automated platform 
development
At this point, a small-scale equivalent had been estab-
lished for each of the five process steps of glycoconjugate 
production (Fig.  1b). In order to create an automated 
sequence of operations for the platform, the microscale 
process, which was split into five discrete steps, had to 
be linked and scripts for the various stages of glycocon-
jugate production were defined. The first production 
stage depicted in Fig.  1b, ‘Cell culture’, was considered 
as four distinct sub-sections, as shown in Fig.  3. These 
sub-sections separated the initial manual handling and 
setup stage of the preculture (Step 1), where additional 
subsequent breakdown was needed to distinguish cul-
ture inoculation, cell growth and culture induction. This 
was mostly due to an integrated feedback loop within 
the script. Following Step 1, the operator loaded the 
preculture and all process solutions onto the automated 
worktable, as shown in Fig. 1c. During Step 2, the opti-
cal density measured at 600 nm  (OD600) of a well-mixed 
preculture sample was measured, before launching an 
executable application which calculated the inoculation 
volume for the desired seeding concentration based upon 
the preculture  OD600 value. The application exported the 
calculated inoculation volumes to a spreadsheet, which 
was then imported into EVOware and used for defin-
ing culture inoculation. The culture was then grown on 
the integrated thermomixer for a predefined duration 
(Step 3). A feedback loop was integrated between Steps 
3 and 4 (Fig.  3), where the executable application was 
again launched following an  OD600 measurement of the 
culture. The application performed a logical test to con-
firm if a given condition was satisfied, returning either 
a TRUE (1) or FALSE (0) value. In this case, the logical 
test checked whether a specified threshold in cell growth 
had been attained before culture induction. The result of 
the logical test was then imported into EVOware where 
two branches of action were possible. The value from the 
executable application (0 OR 1) determined whether the 
EVOware script either induced the culture (1, Step 4) 
or repeated cell growth (0, Step 3) for a shorter interval 
before another  OD600 check was made. This loop was 
repeated hourly until the desired threshold in cell growth 
was achieved. Following induction and incubation (Step 
4), the second production stage in Fig. 1b, ‘Harvest’, was 
scripted onto the automated platform. The harvest  OD600 
was measured for each well before the robotic manipula-
tor arm transferred the plate to the integrated centrifuge 
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(Step 5, Fig.  3). Once each well was pelleted down, the 
liquid handling arm removed the supernatant from each 
well and the third production stage (Fig. 1b), ‘Periplasmic 
extraction’, was performed by the robot (Step 6, Fig.  3). 
Following supernatant removal, EVOware launched the 
executable application, which calculated the resuspen-
sion volume in each well of the periplasmic extraction 
buffer to achieve a matched cell density. The application 
generated a worklist with multiple liquid handling com-
mands, defining the source labware, the volume required 
to aspirate/dispense, the liquid class used, the destination 
labware and the well locations in the source and destina-
tion labware. This worklist was imported and then exe-
cuted in EVOware before the wells were incubated on 
the thermomixer. After the specified incubation for peri-
plasmic extraction, the script for the ‘Separation’ stage 
(Fig. 1b) was written. The microwell plate was transferred 
to the centrifuge where the resultant supernatant was 
kept, containing the product (Step 7, Fig. 3). The periplas-
mic supernatants were then analysed using SDS-PAGE, 
western blotting and ELISA (Step 8, Fig. 3), according to 
“Fluorescent western blotting” and “Sandwich ELISA” 
sections and the final production stage in Fig. 1b. From 
the automated workflow given in Fig.  3, Steps 2–7 are 
automated process steps, performed unsupervised by the 
robot over the course of three days. An operator loads 
the platform on Day 1, defining the variables for culture 
inoculation and induction, before returning on Day 3 to 
run SDS-PAGE/western blot analysis on the samples. The 
executable application also generated cell growth reports 
each instance it was launched over the three days.
The automated process was designed to exclude the 
need for any manual intervention during Steps 2–7, thus 
improving research output and efficiency in comparison 
to manual operations. The feedback loop and execut-
able functions included in the script enable calculation 
and adjustment between culture runs to account for bio-
logical variability and ensure consistency across experi-
ments. This is discussed in the following section. Once 
established, the platform can be used by non-automation 
experts and provides a powerful tool for parallel hands-
free screening of different conditions.
Evaluation of the automated platform robustness
Following the development of the automated platform 
this work then sought to prove technical repeatability 
Fig. 3 Process flow of the operations performed on the automated platform. Executable applications and feedback loops are indicated in italics 
Page 10 of 15Samaras et al. Microb Cell Fact          (2021) 20:104 
and comparability of the automated and manual han-
dling platforms. A proof-of-concept parallel comparison 
was made on a single 24-DSW where the same initial 
cell stock and thermomixer were used to minimise bio-
logical variation and variation in heat distribution with a 
different mixer. A total of 12 repeats per condition were 
completed, where the automated platform was paused 
to execute manual operations. Figure 4 shows the results 
of this investigation. An example western blotting of this 
comparison is given in Fig. 4a which shows the success-
ful production of the bioconjugated ExoA-CPS4 in both 
platforms. Densitometry analysis of the ExoA protein and 
CPS4 glycan bands at ≈ 100 kDa, normalised to a con-
trol condition, showed similar performance between the 
automated and manual platforms in terms of final aver-
age product yield and harvested biomass (+ 26% achieved 
with manual handling). An ELISA analysis showed simi-
lar trends to the western blotting, giving approximately 
35% higher glycan content and similar protein levels 
between the automated and manual handling platforms, 
thus resulting in an improved glycan to protein ratio in 
the product obtained from automated samples (Fig. 4b). 
The slight reduction in yield from the automated plat-
form was likely due to biomass loss during the super-
natant removal at the point of harvest, however a good 
level of consistency across the 12 repeats was achieved 
(15–28% standard deviation in product expression in 
comparison to 8–16% standard deviation from manual 
handling). This demonstrated the successful parallel pro-
duction of glycoconjugate on the developed automated 
platform in addition to similar overall productivity to the 
manual operation achieved with minimal user input.
With any biological process there is an expected level 
of intrinsic variation. In repeating the automated screen-
ing across several weeks, it was possible to investigate 
the extent of biological repeatability on the platform, 
i.e. was similar performance achieved between different 
weeks when handled in the same manner. Three strains 
were investigated, all modified to express the glycopro-
tein of interest as detailed in “Bacterial strains, growth 
conditions and plasmids” section. The relative density of 
glycoconjugate expression from western blotting analy-
sis and the harvested biomass yields are given in Fig. 4c, 
d, respectively. Similar performances between separate 
Fig. 4 Platform robustness and comparability. Technical repeatability investigation between the manual and automated handling platforms; a 
Western blotting and subsequent densitometry analysis showing the presence of ExoA-CPS4 glycoproteins in periplasmic extracts; b Sandwich 
ELISA analysis of periplasmic extracts obtained from both manual and automated cultures; Biological repeatability investigation of three 
glycoconjugate-producing strains repeated over two separate experimental weeks; c Relative quantification of CPS4 glycan and ExoA protein based 
on pixel intensity normalised to a common control condition; d  OD600 of cultures measured pre-induction and at harvest. Statistical significance (*) 
using an unequal variance two-tailed t-test is considered when p ≤ 0.05
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weeks are immediately apparent and were confirmed 
using a two-sample t-test (α = 0.05) between week 1 and 
week 2. No significant statistical difference was found 
for product expression (ExoA-CPS4, Fig.  4c) for any of 
the three strains considered. Similarly, no significant dif-
ference in  OD600 values measured at induction and at 
point of harvest were detected between week 1 and week 
2, with the exception of W3110 strain (strain 1) which 
exhibited ≈ 24% difference between week 1 and week 2 
at point of harvest, (Fig.  4d). This difference will likely 
become negligible with additional repetitions. Overall 
good consistency was observed across the two weeks on 
the automated platform, proving the technical and bio-
logical robustness of the technique.
Application of the automated platform for screening studies
The aim behind the development of the platform was 
to speed up investigation of variables such as different 
strains, different protein carriers and different process 
conditions. The next step in establishing the automated 
platform was to prove the effectiveness of the technique 
for the screening of various conditions simultaneously.
Impact of E. coli strain on glycoconjugate formation Five 
different strains of E. coli were investigated in order to 
identify the most efficient at ExoA-CPS4 glycoconjugate 
production. In order of increasing number of mutations: 
W3110 (Strain 1); CLM37 (Strain 2); CLM24 (Strain 3); 
SDB1 (Strain 4); and Falcon (Strain 5 with no PglB ‘control’ 
or Strain 6), details of which are given in “Bacterial strains, 
growth conditions and plasmids” section and Table 1. All 
strains were transformed with three plasmid-encoded 
components essential for PGCT to work: (1) the glycan 
antigen; (2) the carrier protein; and (3) the PglB OST 
responsible for coupling glycans to protein substrates. 
The plasmids across the five strains were kept the same: 
pB4, responsible for the constitutive expression of the 
CPS4 glycan [31]; pEXT22-PglB, responsible for the IPTG 
inducible expression of the OST coupling enzyme PglB 
(or empty pEXT22 vector for the negative control, S5); 
and pEC415-ExoA(10), responsible for the l-arabinose 
inducible expression of the hyperglycosylatable version of 
carrier protein ExoA [27]. Each column of the 24-DSW 
plate was inoculated with 4 repeats of each strain and 
subsequently underwent all steps outlined in Fig. 3. Gly-
coconjugate expression was then analysed by SDS-PAGE/
western blotting (Fig. 5a) and sandwich ELISA (Fig. 5b). 
The western blot analysis includes two replicates of each 
sample, annotated with Strain 1–6 (S1–S6) depictions. It 
is immediately apparent that Falcon (S6) shows higher lev-
els of ExoA-coupled CPS4 glycan and ExoA carrier pro-
tein expression and exhibits a higher glycan/protein ratio. 
Densitometry analysis of ExoA-CPS4 expression based 
upon the pixel intensity normalised to a control condition 
confirms this. Between the protein and glycan compo-
nents of the glycoconjugate produced, higher CPS4 glycan 
antigen content is desirable for the development and opti-
misation of the bioconjugate pneumococcal vaccine, thus 
the Falcon strain appears to be the most suited for vac-
cine development amongst the variants screened. Product 
expression in the remaining strains appears almost neg-
ligible (< 90% reduction of coupled CPS4 in comparison 
to the Falcon strain), however the strong intensity of the 
CPS4 signal with the Falcon strain saturates any apparent 
expression in the remaining strain variants, thus a sepa-
rate western blotting excluding Falcon (S6) was made. It 
can now be seen that CLM24 (S3) has the second high-
est ExoA-coupled CPS4 yield with an approximate 94% 
decrease in the signal intensity to the Falcon strain. This 
result was confirmed by sandwich ELISA where CLM24 
was shown to yield approximately 92% less ExoA-coupled 
glycan than Falcon, whilst the remaining strains do not 
exceed the ‘background’ threshold, denoted by the dashed 
line, provided by the no-PglB negative control (Strain 
5, Fig. 5b). Increasing the culture volumes tenfold to 20 
mL cultures showed all strains tested are indeed capa-
ble of producing ExoA-CPS4 glycoconjugates, however 
the genetic mutations of CLM24 and Falcon strains are 
clearly beneficial for production of the pneumococcal 
vaccine candidate (Additional file  2: Figure S2). Whilst 
the microscale cultures did not sufficiently identify the 
worst performers, the platform successfully screened for 
the best performing strains, thus rapidly pinpointing the 
conditions worth taking to scale-up experiments.
Impact of PglB expression on glycoconjugate formation A 
second screening study was completed on the robot to 
investigate the effect of PglB induction on glycoconjugate 
formation. This is given in Fig.  5c–e. For this compari-
son the mother strain W3110 (S1) was selected against 
the two W3110-derivatives CLM24 (S3) and Falcon (S6). 
All samples were cultured in quadruplicate and induced 
with either l-arabinose alone to promote ExoA expres-
sion (Lanes 2–7 in the western blotting) or in combina-
tion with IPTG to also promote the expression of the PglB 
OST (Lanes 8–13). PglB in pEXT22 is under the control 
of an IPTG inducible tac promoter [32], so it is interest-
ing to observe protein glycosylation even in the absence 
of IPTG. This is likely due to Lysogeny media contain-
ing traces of lactose, which lead to the mild induction of 
tac promoters, a phenomenon usually circumvented by 
using autoinduction (AI) or defined media formulations 
[33, 34]. This has enabled us to compare the effect of dif-
ferent PglB expression levels on glycoprotein formation. 
The glycoconjugate bands following induction using both 
IPTG and l-arabinose for the Falcon strain show a slight 
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upward shift on the blot, indicating a heavier product 
from enhanced ExoA glycosylation and a larger glycan 
to protein ratio. Densitometry analysis of ExoA-CPS4 
expression based upon the pixel intensity normalised to a 
control condition shows significantly higher glycosylation 
in the Falcon strain (S6, < 95% expression in S1 and S3) 
with a statistically significant boost in protein glycosyla-
tion following IPTG induction of PglB. This is again con-
firmed through analysis using a sandwich ELISA, where 
it is immediately apparent that PglB induction improves 
protein glycosylation and reduces protein expression for 
all the strains tested (Fig.  5d). Although glycoprotein 
formation and glycan coupling are boosted by inducing 
PglB expression, which is advantageous for a glycocon-
jugate vaccine, biomass yields at the point of harvest are 
reduced almost threefold for Falcon (Fig.  5e), similar to 
Fig. 5 Automated screening comparing glycoconjugate expression across multiple strain variants cultured in parallel on the automated platform. 
a–b Comparison across five E. coli strains and a negative control that does not express PglB; a Standard and overexposed western blotting 
showing the presence of ExoA-CPS4 glycoproteins in periplasmic extracts and the subsequent densitometry analysis of the blots based on pixel 
intensity normalised to a control condition; b Sandwich ELISA analysis of periplasmic extracts shown in a. Dashed line showing background CPS4 
glycan signal threshold from negative control strain without PglB; c–e Comparison across three strain variants with and without induction of PglB 
expression; c Western blotting and subsequent densitometry analysis; d Sandwich ELISA analysis of samples shown in c; e  OD600 of Falcon (Strain 
6) cultures, measured pre-induction and at harvest; f–g Comparison of Falcon strain expressing CPS4, PglB (or empty backbone for the negative 
control) and carrier protein ExoA with either 2 or 10 glycosylation sequons from either a pEC415 or pEXT20 plasmid backbone. Expression under 
a DsbA or PelB signal peptide was also compared; f Western blotting and subsequent densitometry analysis; g Sandwich ELISA analysis of extracts 
shown in f. Dashed line showing background CPS4 glycan signal threshold from negative control strain lacking PglB. Statistical significance (*) using 
an unequal variance two-tailed t-test is considered when p ≤ 0.05
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what was previously observed by Ihssen et al. [26] for dif-
ferent bioconjugates and strains. PglB induction caused a 
 104 reduction in viable colony forming units per mL of 
culture (CFU/mL) in comparison to the uninduced sam-
ple, while IPTG induction on the negative control con-
taining an empty pEXT22 vector did not affect biomass 
nor CFU/mL, indicating that higher expression of PglB 
exerts some toxicity to the cells (see Additional file  2: 
Figure S3). A decrease in the final biomass reduces the 
final volumetric productivity of the culture, however the 
features of the product obtained after PglB induction are 
more desirable for a glycoconjugate vaccine (higher gly-
can/protein ratio). Overall, it is evident that the Falcon 
strain exhibited significantly improved glycoconjugate 
expression over the other candidate strains investigated, 
while IPTG-mediated PglB induction was found to boost 
glycosylation of the carrier protein ExoA. This is consid-
ered a more desirable vaccine candidate as the amount of 
pneumococcal antigen per vaccine unit is increased. Fur-
ther optimisation of the strain and plasmid components, 
as well as media composition, and concentration of induc-
ers will be investigated to improve biomass yields.
Impact of  ExoA constructs on  glycoconjugate forma-
tion Following the identification of the Falcon strain as 
the best ExoA-CPS4 glycoprotein producer, the impact of 
different ExoA constructs was investigated (Fig. 5f, g). A 
schematic representation of these constructs is provided 
in Additional File 2: Figure S4. Falcon were transformed 
with the same two plasmids pB4 and pEXT22-PglB, as pre-
viously described, responsible for the constitutive expres-
sion of the CPS4 glycan and the IPTG inducible expression 
of PglB, respectively. The third plasmid responsible for the 
expression of the carrier protein was either the l-arabinose 
inducible pEC415 or the IPTG inducible pEXT20. Both 
plasmids are medium copy vectors, however the plasmid 
copy number per cell of pEXT20 is higher (40 vs. 15–20 
copies/cell). Additionally, the encoded ExoA was N-termi-
nally fused to either DsbA or PelB signal peptides (where 
specifically mentioned, Sec pathway) to investigate their 
effects on periplasmic expression. Lastly, ExoA was modi-
fied to contain either 2 or 10 glycosylation sequons as a 
strategy to modulate the glycan content of the conjugates. 
This is denoted ExoA(2) or ExoA(10). From the western 
blotting analysis shown in Fig. 5f it is apparent that under 
the conditions tested the combination of plasmids where 
ExoA(2) is expressed from pEC415 leads to higher glyco-
protein formation than when expressed from a pEXT20 
backbone, and that almost no product is released into the 
periplasm from the PelB leader signal. The results confirm 
that increasing the number of glycosylation sites from 2 to 
10 leads to enhanced ExoA glycosylation. Densitometry 
analysis of ExoA-CPS4 expression based upon the pixel 
intensity from the western blot shows a significant differ-
ence between the pEC415 and pEXT20 product expres-
sion levels and also between the DsbA and PelB periplas-
mic signals. An almost fivefold increase in glycosylation 
was shown between + pEC415-ExoA(2) and + pEC415-
ExoA(10). Secondary analysis with ELISA showed simi-
lar results with DsbA clearly outperforming PelB as a 
periplasmic signal for ExoA (Fig. 5g). ExoA(10) was also 
shown to be threefold more glycosylated then ExoA(2), 
proving an effective strategy to adjust the amount of 
glycan antigen in the vaccine preparation. The pEC415 
backbone shows a 3–5% increase in glycosylation in com-
parison to the pEXT20 construct, although a significant 
improvement is visible from the western blotting. Overall, 
this work showed the more favourable combination of the 
pEC415 backbone co-expressed with the DsbA signal for 
glycoprotein expression. Additionally, it showed that the 
amount of glycan antigen can be successfully modulated 
through the inclusion of a varying number of glycosyla-
tion sequons on the carrier protein.
Estimating the  value and  advantages of  the  automated 
platform One of the greatest advantages of an auto-
mated platform, once proven fully effective in terms 
of successful and reproducible production, is the large 
reduction in manual handling hours for screening opera-
tions. With each screening experiment detailed in this 
work, a total of 6–8 different culture conditions were 
investigated, and 24 individual cultures were completed 
per experimental run. A conservative model Gantt chart 
of the manual working hours involved from the concep-
tion of preculture to the final western blot analysis is given 
in Additional file 2: Figure S5). This chart considers two 
scenarios; a manually handled culture from preculture 
to inoculation on a 24-DSW plate with the subsequent 
harvest, lysis and analysis steps over the course of one 
week, and the equivalent steps when an automated plat-
form is employed. From this model a bar chart showing 
the amount of manual handling hours per well completed 
(see Additional file 2: Figure S6) shows that the use of an 
automated method results in approximately double the 
efficiency in comparison to manual handling. In addition, 
the robot is capable of unsupervised, walk-away screening 
studies, thus increasing researcher output within a given 
week. During the early research phase of vaccine develop-
ment, this is a vital reduction in both time and monetary 
resources, speeding up the advancement and selection of 
vaccine candidates to preclinical and clinical trials.
Conclusions
An automated microscale platform was developed to pro-
vide unsupervised ‘walk away’ operation, capable of screen-
ing multiple vaccine candidates in parallel. When developing 
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higher throughput screening techniques, process robustness 
is paramount. Evaluation of the automated platform devel-
oped in this work showed overall good consistency both 
with technical and biological repeats. This proved successful 
integration with a numerical programming platform, which 
incorporated process adaptability and an automated deci-
sional tool, in addition to liquid handling operations.
The desired application of the automated platform was 
the microscale screening of multiple conditions in paral-
lel. Three separate screening studies are reported in this 
work. The first evaluated the differences in glycoconjugate 
expression and biomass for five different E. coli strains, 
whilst another investigated the impact of PglB expres-
sion on glycoconjugate formation. A clear improvement 
in product expression and glycosylation was found with 
the best producing Falcon strain upon induction of PglB. 
A third screening study investigated the impact of two 
different plasmid backbones, two periplasmic signals, 
and the number of glycosylation sites in ExoA on glyco-
protein expression/recovery. The screening indicated 
that ExoA with a DsbA signal peptide expressed from a 
pEC415 l-arabinose inducible plasmid, in concert with 
PglB expressed from a pEXT22 backbone and pB4, leads 
to increased glycoprotein formation (at least in E. coli 
strain Falcon). Additionally, it was shown that the amount 
of CPS4 glycan antigen in the vaccine candidate increases 
with the number of glycosylation sites per carrier protein. 
Overall, 24 different culture conditions were investigated 
and a total of 120 individual cultures were completed. 
Minimal manual handling hours were needed to com-
plete these experiments, highlighting the superiority and 
efficiency of higher throughput automated screening plat-
forms, especially during early phase vaccine research.
The continuous feedback between the cell engineer-
ing aspect of this work and the design of the microscale 
platform is novel to the field of glycoengineering of vac-
cines. This collective approach speeds up the targeted 
development of operations most appropriate in advanc-
ing the early research phase of vaccines. The successful 
production of glycoconjugate vaccines in the biotech-
nology workhorse bacterium E. coli holds great poten-
tial in alleviating the cost burden currently associated 
with available vaccines targeted against pneumococcal 
disease. Understanding how to best optimise this sys-
tem is paramount to develop a feasible bioconjugate 
alternative at a fraction of the current cost.
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